Effects of over-expressing resistin on glucose and lipid metabolism in mice

Resistin,a newly discovered peptide hormone mainly secreted by adipose tissues,is present at high levels in serum of obese mice and may be a potential link between obesity and insulin resistance in rodents. However,some studies of rat and mouse models have associated insulin resistance and obesity with decreased resistin expression. In humans,no relationship between resistin level and insulin resistance or adiposity was observed. This suggests that additional studies are necessary to determine the specific role of resistin in the regulation of energy metabolism and adipogenesis. In the present study,we investigated the effect of resistin in vivo on glucose and lipid metabolism by over-expressing resistin in mice by intramuscular injection of a recombinant eukaryotic expression vector pcDNA3.1-Retn encoding porcine resistin gene. After injection,serum resistin and serum glucose (GLU) levels were significantly increased in the pcDNA3.1-Retn-treated mice; there was an obvious difference in total cholesterol (TC) level between the experiment and the control groups on Day 30. In pcDNA3.1-Retn-treated mice,both free fatty acid (FFA) and high density lipoprotein (HDL) cholesterol levels were markedly lower than those of control,whereas HDL cholesterol and triglyceride (TG) levels did not differ between the two groups. Furthermore,lipase activity was expressly lower on Day 20. Our data suggest that resistin over-expressed in mice might be responsible for insulin resistance and parameters related to glucose and lipid metabolism were changed accordingly.

Spin polarization and production rate studies of surface muons in a novel solenoid capture system based on CSNS

A novel surface muon capture system with a large acceptance was proposed based on the China spallation neutron source(CSNS).This system was designed using a superconducting solenoid where a long graphite target was put inside it.Firstly,the spin polarization evolution was studied in a constant uniform magnetic field.As the magnetic field can interact with the spin of the surface muon,both the spin polarization and production rate of the surface muons collected by the new capture system were calculated by the G4beamline.Simulation results showed that the surface muons could still keep a high spin polarization([90%)with different magnetic fields(0–10 T),and the larger magnetic field is,the more surface muons can be captured.Finally,the proton phase space,Courant–Snyder parameters,and intensities of surface muons of different beam fractions were given with magnetic fields of 0 and 5T.The solenoid capture system can focus proton and surface muon beams and collect p?and l?particles.It can also provide an intense energetic positron source.

Efficacy and Safety of Tenofovir and Lamivudine in Combination with Efavirenz in Patients Co-infected with Human Immunodeficiency Virus and Hepatitis B Virus in China

Background： The prevalence of hepatitis B virus （HBV） infection is high among individuals infected with human immunodeficiency virus （HIV） in China.Both HIV and HBV can be treated with tenofovir disoproxil fumarate （TDF） and lamivudine （3TC）, so we evaluated the safety and efficacy of combination antiretroviral therapy （ART） that included TDF, 3TC, and efavirenz （EFV） among ART-naive individuals who were co-infected with HIV and HBV.Methods： One hundred HIV/HBV co-infected ARV-naive individuals were started on the regimen ofTDF, 3TC, and EFV, and the levels of plasma HBV DNA, HIV RNA, and biochemical evaluation related to the function of liver and kidney were analyzed.Results： Concerning efficacy, this study found that by week 48, the vast majority co-infected participants receiving this ART regimen had undetectable HBV DNA levels （71%） and/or HIV RNA levels （90%）.Concerning safety, this study found that the median estimated glomerular filtration rate of participants decreased from baseline （109 ml＆#183;min-1＆#183; 1.73 m-2） to week 12 （104 ml＆#183;min-1＆#183; 1.73 m-2） but was almost back to baseline at week 48 （1 1 1 ml＆#183;min-1＆#183; 1.73 m-2）.Conclusion： This combination ART regimen is safe and effective for patients with HIV/HBV co-infection.Trial Registration： ClinicalTrials.gov, NCT01751555;https：//clinicaltrials.gov/ct2/show/NCT01751555.